Stockscreener 앱 받기
2.54
11.19%
-0.32
시간 외 거래:
2.54
전일 마감가:
$2.86
열려 있는:
$2.71
하루 거래량:
61,571
Relative Volume:
0.67
시가총액:
$61.88M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-28.25%
1개월 성능:
-35.20%
6개월 성능:
-83.51%
1년 성능:
+0.00%
1일 변동 폭
$2.50
$2.80
1주일 범위
$2.50
$3.65
52주 변동 폭
$2.50
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
명칭
Artiva Biotherapeutics Inc
전화
(858) 267-4467
주소
5505 MOREHOUSE DRIVE, SAN DIEGO
ARTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
2.54 | 61.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 개시 | Jefferies | Buy |
| 2024-08-13 | 개시 | Needham | Buy |
| 2024-08-13 | 개시 | TD Cowen | Buy |
| 2024-08-13 | 개시 | Wedbush | Outperform |
모두보기
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Artiva Biotherapeutics Reports 2024 Financial Results - TipRanks
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year - Investing.com Canada
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year By Investing.com - Investing.com South Africa
What is Wedbush’s Forecast for ARTV Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for ARTV Earnings - Defense World
Brokers Issue Forecasts for ARTV Q1 Earnings - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Earns “Buy” Rating from HC Wainwright - Defense World
Cantor Fitzgerald Issues Negative Outlook for ARTV Earnings - Defense World
Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability - TipRanks
Artiva Biotherapeutics stock rises following analyst optimism By Investing.com - Investing.com South Africa
Artiva Biotherapeutics stock rises following analyst optimism - Investing.com
Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor Fitzgerald - Defense World
Artiva Biotherapeutics’ (ARTV) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NK Cell Therapy Pipeline 2025: Key Developments, Emerging - openPR.com
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics Reports Full Year 2024 Results and Updates on AlloNK® Autoimmune Program with Key Leadership Strengthening - Nasdaq
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - Business Wire
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Allogeneic CAR-T Cell Patent Landscape and Forecast Report - GlobeNewswire
Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen - Yahoo Finance
Rhumbline Advisers Has $130,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Tuesday - Defense World
My Favorite "Magnificent Seven" Stock Just Joined the Quantum Computing Revolution (Hint: It's Not Nvidia) - The Globe and Mail
Nk Cell Therapy Pipeline 2024: FDA Updates, Therapy - openPR
Autodesk Designs Value for Investors: Uptrend Set to Continue - The Globe and Mail
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Financial Comparison: Compugen (NASDAQ:CGEN) & Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - Citeline News & Insights
JPMorgan Chase & Co. Buys New Holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics appoints new director and committee members - Investing.com India
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewswire
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Natural killer cells, a rising alternative to CAR-T cell therapy - PharmaVoice
Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00 - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Predicts ARTV FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2025 Earnings - MarketBeat
Artiva Biotherapeutics Inc (ARTV) 재무 분석
Artiva Biotherapeutics Inc (ARTV)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):